Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science...
-
STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science...
-
STOCKHOLM den 26 april 2018. Vid Karolinska Developments årsstämma som hölls den 26 april 2018 beslutade aktieägarna, följande: Redovisning: beslutades att fastställa av resultaträkning och...
-
STOCKHOLM - April 26, 2018. At the Annual General Meeting of Karolinska Development AB held April 26, 2018, the following resolutions were passed: Profit and loss statement and the balance sheet: It...
-
STOCKHOLM - den 25 april 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - mars 2018. Den fulla rapporten är tillgänglig på bolagets hemsida....
-
STOCKHOLM - 25 April 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - March 2018. The full report is available on the Company's...
-
STOCKHOLM, 18 April, 2018. Karolinska Development's portfolio company Modus Therapeutics candidate drug sevuparin has been granted rare pediatric disease designation by the US Food & Drug...
-
STOCKHOLM, 18 April, 2018. Karolinska Development's portfolio company Modus Therapeutics candidate drug sevuparin has been granted rare pediatric disease designation by the US Food & Drug...
-
STOCKHOLM - den 16 april 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) tillkännager idag att portföljbolaget Aprea Therapeutics presenterar initiala positiva resultat vid årsmötet 2018...
-
STOCKHOLM - 16 April 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics is presenting initial positive results at the 2018...